Atlas Trials

Third Line or Later (3L+) HER2+ Breast Cancer

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Third Line or Later (3L+) HER2+ Breast Cancer

RecordFirmDate
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609)Ascendis Pharma Oncology Division A/S2022-01-11

Track Third Line or Later (3L+) HER2+ Breast Cancer automatically

Every clearance here is in the API, with alerts when new ones post.